Inhaled antimicrobial therapies for respiratory infections

Current Infectious Disease Reports

Volumn 10, Issue 1, 2008, Pages 29-36

  Kim, Shin Woo ^b   Kuti, Joseph L ^b   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIMYCOBACTERIAL AGENT; ANTIVIRUS AGENT; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; COTRIMOXAZOLE; DAPSONE; FLUCONAZOLE; ITRACONAZOLE; NKTR 061; PENICILLIN DERIVATIVE; PENTAMIDINE ISETHIONATE; PLACEBO; RIBAVIRIN; TOBRAMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN; ZANAMIVIR;

ADJUVANT THERAPY; AEROSOL; ANTIVIRAL ACTIVITY; ASPERGILLOSIS; BRONCHIECTASIS; BRONCHOSPASM; CLINICAL TRIAL; COUGHING; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG FATALITY; DRUG HYDROLYSIS; DRUG INDICATION; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG SPUTUM LEVEL; DRUG STABILITY; DYSPHAGIA; DYSPNEA; ERADICATION THERAPY; FORCED EXPIRATORY VOLUME; HOSPITAL INFECTION; HUMAN; INFLUENZA; LUNG ASPERGILLOSIS; METERED DOSE INHALER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; MULTIPLE CYCLE TREATMENT; MYCOBACTERIOSIS; MYCOSIS; NAUSEA; NEBULIZER; NONHUMAN; PNEUMOCYSTIS PNEUMONIA; RESPIRATORY DISTRESS; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; STAPHYLOCOCCUS INFECTION; TASTE DISORDER; UNSPECIFIED SIDE EFFECT; VENTILATOR ASSOCIATED PNEUMONIA; VIRUS INFECTION; VOMITING;

EID: 41049083162     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-008-0007-x     Document Type: Review

References (67)

1. American Thoracic Society: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416.
2. Silveira F, Paterson DL: Pulmonary fungal infections. Curr Opin Pulm Med 2005, 11:242-246.
3. Wood GC, Swanson JM: Aerosolised antibacterials for the prevention and treatment of hospital-acquired pneumonia. Drugs 2007, 67:903-914.
4. Flume P, Klepser ME: The rationale for aerosolized antibiotics. Pharmacotherapy 2002, 22:71S-79S.
5. Klepser ME: Role of nebulized antibiotics for the treatment of respiratory infections. Curr Opin Infect Dis 2004, 17:109-112.
6. Hagerman JK, Hancock KE, Klepser ME: Aerosolised antibiotics: a critical appraisal of their use. Expert Opin Drug Deliv 2006, 3:71-86.
7. Drew R: Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections. Int J Antimicrob Agents 2006, 27S:36-44.
8. Prober CG, Walson PD, Jones J: Technical report: precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs. Pediatrics 2000, 106:E89.
9. Weber A, Morlin G, Cohen M, et al.: Effect of nebulizer type and antibiotic concentration on device performance. Pediatr Pulmonol 1997, 23:249-260.
10. Geller DE: Choosing a nebulizer for cystic fibrosis applications. Curr Opin Pulm Med 1997, 3:414-419.
11. Shirk MB, Donahue KR, Shirvani J: Unlabeled uses of nebulized medications. Am J Health Syst Pharm 2006, 63:1704-1716.
12. Eisenberg J, Pepe M, Williams-Warren J, et al.: A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group. Chest 1997, 111:955-962.
13. de Boer AH, Le Brun PP, van der Woude HG, et al.: Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 1: development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as de-agglomeration principle. Eur J Pharm Biopharm 2002, 54:17-24.
14. Le Brun PP, de Boer AH, Mannes GP, et al.: Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. Eur J Pharm Biopharm 2002, 54:25-32.
15. Miller DD, Amin MM, Palmer LB, et al.: Aerosol delivery and modern mechanical ventilation: in vitro/in vivo evaluation. Am J Respir Crit Care Med 2003, 168:1205-1209.
16. Newhouse MT, Hirst PH, Duddu SP, et al.: Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest 2003, 124:360-366.
17. Geller DE, Konstan MW, Smith J, et al.: Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 2007, 42:307-313.
18. US Food and Drug Administration: Center for Drug Evaluation and Research Alert: Colistimethate (marketed as Coly-Mycin M and generic products) Information. Available at www.fda.gov/cder/drug/infopage/ colistimethate/default.htm. Accessed October 18, 2007.
19. Ilowite JS, Gorvoy JD, Smaldone GC: Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis 1987, 136:1445-1449.
20. Geller DE, Pitlick WH, Nardella PA, et al.: Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002, 122:219-226.
21. Baran D, de Vuyst P, Ooms HA: Concentration of tobramycin given by aerosol in the fluid obtained by bronchoalveolar lavage. Respir Med 1990, 84:203-204.
22. Le Conte P, Potel G, Peltier P, et al.: Lung distribution and pharmacokinetics of aerosolized tobramycin. Am Rev Respir Dis 1993, 147:1279-1282.
23. Ratjen F, Rietschel E, Kasel D, et al.: Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 2006, 57:306-311.
24. Weber A, Williams-Warren J, Ramsey B, et al.: Tobramycin serum concentrations after aerosol and oral administration in cystic fibrosis. Am J Ther 1995, 2:81-87.
25. Smith AL, Ramsey BW, Hedges DL, et al.: Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol 1989, 7:265-271.
26. Gibson RL, Emerson J, McNamara S, et al.: Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003, 167:841-849.
27. Jensen T, Pedersen SS, Garne S, et al.: Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987, 19:831-838.
28. Ramsey BW, Pepe SS, Quan JM, et al.: Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999, 340:23-30.
29. Stelmach I, Korzeniewska A, Stelmach W: Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland. Respiration 2007, [Epub ahead of print].
30. Hodson ME, Gallagher CG: New clinical evidence from the European tobramycin trial in cystic fibrosis. J Cyst Fibros 2002, 1(Suppl 2):199-202.
31. Westerman EM, DeBoer AH, LeBrun PP, et al.: Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. J Cyst Fibros 2007, 6:284-292.
32. Alothman GA, Ho B, Alsaadi MM, et al.: Bronchial constriction and inhaled colistin in cystic fibrosis. Chest 2005, 127:522-529.
33. Barker AF, Couch L, Fiel SB, et al.: Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000, 162:481-485.
34. Bilton D, Henig N, Morrissey B, et al.: Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006, 130:1503-1510.
35. Wood GC, Boucher BA, Croce MA, et al.: Aerosolized ceftazidime for prevention of ventilator-associated pneumonia and drug effects on the proinflammatory response in critically ill trauma patients. Pharmacotherapy 2002, 22:972-982.
36. Claridge JA, Edwards NM, Swanson J, et al.: Aerosolized ceftazidime prophylaxis against ventilator-associated pneumonia in high-risk trauma patients: results of a double-blind randomized study. Surg Infect (Larchmt) 2007, 8:83-90.
37. Brown RB, Kruse JA, Counts GW, et al.: Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. The Endotracheal Tobramycin Study Group. Antimicrob Agents Chemother 1990, 34:269-272.
38. Michalopoulos A, Kasiakou SK, Mastora Z, et al.: Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005, 9:R53-59.
39. Hamer DH: Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 2000, 162:328-330.
40. Kwa AL, Loh C, Low JG, et al.: Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2005, 41:754-757.
41. Maiz L, Canton R, Mir N, et al.: Aerosolized vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. Pediatr Pulmonol 1998, 26:287-289.
42. Weathers L, Riggs D, Santeiro M, et al.: Aerosolized vancomycin for treatment of airway colonization by methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 1990, 9:220-221.
43. Gradon JD, Wu EH, Lutwick LI: Aerosolized vancomycin therapy facilitating nursing home placement. Ann Pharmacother 1992, 26:209-210.
44. Nektar Therapeutics: Nektar Therapeutics announces Phase 2a clinical results regarding the use of NKTR-061 (inhaled amikacin) to threat gram-negative hospital-acquired pneumonia presented at the Annual American Thoracic Society International Conference [news release]. Available at http://www.nektar.com/wt/page/pr_244648/ ?ref=Media_Press_Releases. Accessed November 2, 2007.
45. Morgan J, Wannemuehler KA, Marr KA, et al.: Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005, 43:S49-S58.
46. Dummer JS, Lazariashvilli N, Barnes J, et al.: A survey of antifungal management in lung transplantation. J Heart Lung Transplant 2004, 23:1376-1381.
47. Schwartz S, Behre G, Heinemann V, et al.: Aerosolized amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 1999, 93:3654-3661.
48. Hertenstein B, Kern WV, Schmeiser T, et al.: Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia. Ann Hematol 1994, 68:21-26.
49. Reichenspurner H, Gamberg P, Nitschke M, et al.: Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 1997, 29:627-628.
50. Allen SD, Sorensen KN, Nejdl MJ, et al.: Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. J Antimicrob Chemother 1994, 34:1001-1013.
51. Cicogna CE, White MH, Bernard EM, et al.: Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1997, 41:259-261.
52. Drew RH, Dodds Ashley E, Benjamin DK Jr, et al.: Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004, 77:232-237.
53. Palmer SM, Drew RH, Whitehouse JD, et al.: Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001, 72:545-548.
54. Lowry CM, Marty FM, Vargas SO, et al.: Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study. Transpl Infect Dis 2007, 9:121-125.
55. Alexander BD, Dodds Ashley ES, Addison RM, et al.: Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2006, 8:13-20.
56. Purcell IF, Corris PA: Use of nebulized liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema. Thorax 1995, 50:1321-1323.
57. Safdar A, O'Brien S, Kouri IF: Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis. Bone Marrow Transplant 2004, 34:467-468.
58. Hoeben BJ, Burgess DS, McConville JT, et al.: In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2006, 50:1552-1554.
59. Alvarez CA, Wiederhold NP, McConville JT, et al.: Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis. J Infect 2007, 55:68-74.
60. Leoung GS, Feigal DW Jr, Montgomery AB, et al.: Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial. N Engl J Med 1990, 323:769-775.
61. Montgomery AB, Debs RJ, Luce JM, et al.: Aerosolized pentamidine as second line therapy in patients with AIDS and Pneumocystis carinii pneumonia. Chest 1989, 95:747-750.
62. Pretet S, Salmon D, Rousseau F, et al.: Long-term results of monthly inhaled pentamidine as primary prophylaxis of Pneumocystis carinii pneumonia in HIV-infected patients. Am J Med 1993, 94:35-40.
63. Vasconcelles MJ, Bernardo MV, King C, et al.: Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increases risk of other infections. Biol Blood Marrow Transplant 2000, 6:35-43.
64. Marras TK, Sanders K, Lipton JH, et al.: Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogenic marrow transplantation. Transpl Infect Dis 2002, 4:66-74.
65. Ventre K, Randolph AG: Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 2007:CD000181.
66. Falsey AR: Respiratory syncytial virus infection in adults. Semin Respir Crit Care Med 2007, 28:171-181.
67. Cheer SM, Wagstaff AJ: Zanamivir: an update of its use in influenza. Drugs 2002, 62:71-106.